07:00 , Jun 25, 2009 |  BC Innovations  |  Strategy

Science for export

Although every major university or institute would like to be located in a biotech hub and keep its discoveries close to home, only a few true hubs exist. For everyone else, the question is whether...
07:00 , Oct 15, 2007 |  BioCentury  |  Emerging Company Profile

Corporate Profile

BioVascular Inc. San Diego, Calif. Technology: Therapeutics for platelet-mediated disorders Disease focus: Cardiovascular Clinical status: Phase I/II Founded: 2005 by John Parrish and Paul Glidden University collaborators: None Corporate partners: None Number of employees: 8...
07:00 , Oct 15, 2007 |  BioCentury  |  Emerging Company Profile

BioVascular: Platelet mediation

Preventing vascular graft failure by pharmaceutical means is not an area that has seen much success, but BioVascular Inc. hopes its saratin can prevent the buildup of platelets inside blood vessels that often causes graft...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Clinical News

BVI-007: Phase Ia started

BioVascular began a Phase Ia trial in healthy volunteers. BioVascular acquired BVI-007 through last week's merger with Revitus Inc. BioVascular Inc. , San Diego, Calif.   Product: BVI-007   Business: Cardiovascular   Molecular target: Thrombopoietin...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Company News

BioVascular board of directors update

BioVascular Inc. , San Diego, Calif.   Business: Cardiovascular   Appointed: Stephen Hanson, former CEO of Revitus Inc. (now part of BioVascular)  ...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Company News

BioVascular, Revitus Inc. deal

BioVascular and Revitus merged under undisclosed terms. The merged company will be called BioVascular and will be headquartered in San Diego. BioVascular's lead compound is saratin , a recombinant polypeptide that is in two Phase...